Skip to main content
. Author manuscript; available in PMC: 2019 Jan 28.
Published in final edited form as: Expert Rev Clin Pharmacol. 2017 May 22;10(8):899–910. doi: 10.1080/17512433.2017.1329009

Figure 1.

Figure 1.

Simplified GRAPPA treatment recommendations [4].

*combination csDMARDS and TNFi common in clinical practice. **Conditional recommendations: At the time these recommendations were published, these drugs were not approved or recommendations were based on data from abstracts. csDMARD, conventional synthetic DMARD; CSA, cyclosporin A; GRAPPA, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis; IL-17i, interleukin-17 inhibitor; IL-12/23i, interleukin-12/23 inhibitor; LEF, leflunomide; MTX, methotrexate; NSAIDS, nonsteroidal anti-inflammatory drugs; PDE-4i, phosphodiesterase 4 inhibitor; SSZ, sulfasalazine; tsDMARD, targeted synthetic DMARD; TNFi, tumor necrosis factor inhibitor